BioLine RX Stock

BioLine RX Gross Margin

The Gross Margin of BioLine RX (BLRX.TA) as of Mar 19, 2026 is 0.68.In the previous year, Gross Margin was 0.23 — a change of 194.55% (higher).

Gross Margin

0.68

YoY

194.55%

Last updated:

Gross Margin of BioLine RX is 2026 0.68 . Gross Margin of BioLine RX was 2025 0.23 . It decreases by 194.55% higher compared to the previous year.
Access this data via the Eulerpool API

BioLine RX Stock analysis

What does BioLine RX do? BioLine RX Ltd is a global biopharmaceutical company specializing in the development of novel therapies for cancer and other serious diseases. The company is headquartered in Israel and has offices in the United States and Europe. BioLine RX is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioLine RX stock

Gross Margin of BioLine RX amounted to 0.23 0.68

Access this data via the Eulerpool API

Margins — BioLine RX

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

All Key Metrics — BioLine RX